We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Juventas Therapeutics Reports One Year Data from Phase I Heart Failure Clinical Trial

News   Jan 31, 2012

 
Juventas Therapeutics Reports One Year Data from Phase I Heart Failure Clinical Trial
 
 
 

RELATED ARTICLES

Antibody Therapy That Trains Phagocytes to Destroy Tumors Is Tested in Patients

News

An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.

READ MORE

A Way to Improve Cancer Immunotherapy?

News

A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.

READ MORE

“Smart Drug” Shows Promise for Metastatic Triple-Negative Breast Cancer

News

A new "smart drug" has shown promise for women with metastatic triple-negative breast cancer, based on data from a clinical trial at NewYork-Presbyterian/Columbia's Herbert Irving Comprehensive Cancer Center and other centers.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE